Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice

被引:0
|
作者
James F. O’Mahony
Anthony T. Newall
Joost van Rosmalen
机构
[1] Trinity College Dublin,Department of Health Policy and Management, School of Medicine
[2] University of New South Wales,School of Public Health and Community Medicine
[3] Erasmus MC,Department of Biostatistics
来源
PharmacoEconomics | 2015年 / 33卷
关键词
Discount Rate; Cycle Length; Health Economic Evaluation; Implementation Period; Shared Effect;
D O I
暂无
中图分类号
学科分类号
摘要
Time is an important aspect of health economic evaluation, as the timing and duration of clinical events, healthcare interventions and their consequences all affect estimated costs and effects. These issues should be reflected in the design of health economic models. This article considers three important aspects of time in modelling: (1) which cohorts to simulate and how far into the future to extend the analysis; (2) the simulation of time, including the difference between discrete-time and continuous-time models, cycle lengths, and converting rates and probabilities; and (3) discounting future costs and effects to their present values. We provide a methodological overview of these issues and make recommendations to help inform both the conduct of cost-effectiveness analyses and the interpretation of their results. For choosing which cohorts to simulate and how many, we suggest analysts carefully assess potential reasons for variation in cost effectiveness between cohorts and the feasibility of subgroup-specific recommendations. For the simulation of time, we recommend using short cycles or continuous-time models to avoid biases and the need for half-cycle corrections, and provide advice on the correct conversion of transition probabilities in state transition models. Finally, for discounting, analysts should not only follow current guidance and report how discounting was conducted, especially in the case of differential discounting, but also seek to develop an understanding of its rationale. Our overall recommendations are that analysts explicitly state and justify their modelling choices regarding time and consider how alternative choices may impact on results.
引用
收藏
页码:1255 / 1268
页数:13
相关论文
共 50 条
  • [1] Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice
    O'Mahony, James F.
    Newall, Anthony T.
    van Rosmalen, Joost
    [J]. PHARMACOECONOMICS, 2015, 33 (12) : 1255 - 1268
  • [2] Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice
    Manuel Gomes
    Elizabeth Murray
    James Raftery
    [J]. PharmacoEconomics, 2022, 40 : 367 - 378
  • [3] Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice
    Gomes, Manuel
    Murray, Elizabeth
    Raftery, James
    [J]. PHARMACOECONOMICS, 2022, 40 (04) : 367 - 378
  • [4] Health economic evaluation of digital nursing technologies: a review of methodological recommendations
    Huter, Kai
    Krick, Tobias
    Rothgang, Heinz
    [J]. HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [5] Health economic evaluation of digital nursing technologies: a review of methodological recommendations
    Kai Huter
    Tobias Krick
    Heinz Rothgang
    [J]. Health Economics Review, 12
  • [6] Addressing methodological and ethical issues in practicing health economic evaluation in China
    Jiang, Shan
    Chen, Zhuo
    Wu, Jing
    Zang, Xiao
    Jiang, Yawen
    [J]. JOURNAL OF GLOBAL HEALTH, 2020, 10 (02)
  • [7] Methodological issues for the economic evaluation of health interventions: a concise state of the art
    Di Tanna, Gian Luca
    Baio, Gianluca
    [J]. EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2013, 10 (02)
  • [8] DEALING WITH THE PAST: METHODOLOGICAL ISSUES
    Sluglett, Peter
    [J]. WRITING THE MODERN HISTORY OF IRAQ: HISTORIOGRAPHICAL AND POLITICAL CHALLENGES, 2012, : 1 - 12
  • [9] Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges
    Fugel, Hans-Joerg
    Nuijten, Mark
    Postma, Maarten
    Redekop, Ken
    [J]. FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [10] Economic evaluation of cancer treatments: methodological and practical issues
    Uyl-de Groot, CA
    Touw, CKR
    [J]. ANTI-CANCER DRUGS, 1998, 9 (10) : 835 - 841